Innova Captab
- Market cap
- ₹ 5,623 Cr.
- P/E
- 39x
- P/B
- 5.23x
- 52-week range
- 622 – 1,353.5
- ROE
- 14%
- ROCE
- 15%
- Dividend yield
- 0.2%
- Debt / equity
- 0.32
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Innova Captab Limited is an India-based integrated pharmaceutical company. The Company is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It has pharmaceuticals value chain, including research and development, manufacturing, drug distribution and marketing and exports. Its business includes Contract Development and Manufacturing (CDMO) Services and Products, Domestic Branded Generics, and International Branded Generics. Its CDMO business provides research, product development and manufacturing services. Its Branded Generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under its own brand names through online and offline channels. Its generic drug products are also available online through various e-commerce pharmacy sites. It has developed a diversified branded generics product portfolio including tablets, capsules, dry syrups, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Innova Captab against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)39 against a typical 34.3: pricier than most peers (1st = cheapest).127th of 220
- Sales growth+33.8% against a typical +15.6% from a year earlier.50th of 197
- Profit growth+41.9% against a typical +18.9% from a year earlier.59th of 160
- Share price, 3 months+8% against a typical 0%.67th of 200
- Size₹ 5,623 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).52nd of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A+ | Stable | 7 Oct 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 7 Oct 2026 | ▲ Upgrade1 notch | CARE A → CARE A+ | Low | CARE | ₹ 459.6 Cr. | |
| 17 Apr 2026 | Reaffirmed | CARE A | — | CARE | ₹ 466.72 Cr. | |
| 19 Sep 2025 | Reaffirmed | CARE A | — | CARE | ₹ 409.38 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 21 Aug 2026 | Financial Results | To consider, approve and take on record, the revision of standalone and consolidated financial statements of the Company for the quarter and financial year ended 31st March, 2026, due to certain inadvertent error(s) were identified in the financial statements of the Company, including in the financial statements of the entities which form part of the group prior to the adoption of such financial statements at the ensuing annual general meeting. |
| 11 Aug 2026 | Financial Results | To consider and approve the revised Audited Standalone Financial Result of the Company for the quarter and financial year ended 31st March 2026 along with Statement of Cash Flow and Statement of Assets and Liabilities as on 31st March, 2026.This revision has been necessitated on account of an inadvertent error(s) which is immaterial in nature. |
| 7 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 23 Jan 2026 | Financial Results/Dividend/Other business matters | Intimation of Board Meeting under Regulations 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (i) for consideration of Unaudited (Standalone and Consolidated) financial results for the quarter and nine months ended 31st December, 2025 and (ii) consideration of declaration of interim dividend |
| 7 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the quarter and half year ended September 30, 2025 and other business matters |
| 7 Aug 2025 | Financial Results | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of Innova Captab Limited ( the Company ), is scheduled to be held on Thursday, 07th August, 2025, inter alia, to consider, approve and take on record, the Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended 30th June, 2025.Further, pursuant to the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company which was closed from Tuesday, 01st July, 2025, for all the designated persons and their immediate relatives shall re-open after the expiry of 48 hours from the date of declaration of the said financial results. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 283 | 302 | 263 | 294 | 318 | 316 | 315 | 352 | 380 | 450 | 448 | 471 |
| Expenses | 242 | 258 | 225 | 252 | 268 | 270 | 267 | 299 | 329 | 381 | 383 | 398 |
| Operating Profit | 40 | 45 | 38 | 42 | 50 | 47 | 48 | 52 | 52 | 69 | 65 | 73 |
| OPM % | 14% | 15% | 14% | 14% | 16% | 15% | 15% | 15% | 14% | 15% | 15% | 16% |
| Other Income | 3 | 2 | 6 | 2 | 2 | 4 | 3 | 4 | 4 | 2 | 2 | 2 |
| Interest | 9 | 7 | 1 | 0 | 0 | 0 | 2 | 3 | 6 | 4 | 5 | 4 |
| Depreciation | 5 | 5 | 3 | 5 | 5 | 5 | 10 | 11 | 11 | 11 | 11 | 12 |
| Profit before tax | 30 | 35 | 40 | 39 | 47 | 46 | 39 | 43 | 39 | 56 | 51 | 59 |
| Tax % | 24% | 29% | 27% | 25% | 25% | 25% | 25% | 27% | 24% | 24% | 25% | 25% |
| Net Profit | 23 | 25 | 29 | 29 | 35 | 34 | 30 | 31 | 30 | 42 | 38 | 44 |
| EPS in Rs | 4.77 | 4.39 | 5.02 | 5.15 | 6.12 | 5.98 | 5.17 | 5.42 | 5.18 | 7.37 | 6.65 | 7.71 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 32%
- 3 Years
- 21%
- TTM
- 34%
- 10 Years
- —
- 5 Years
- 32%
- 3 Years
- 28%
- TTM
- 19%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 17%
- 3 Years
- 15%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Innova Captab | ₹ 1,047.40 | ₹ 5,623 Cr. | 39x | 5.2x | 14% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Lokesh Bhasin
- Chief Financial Officer
- Neeharika Shukla
- Compliance Officer, Company Secretary
- Vinay Kumar Lohariwala
- Managing Director, Executive Director
- Manoj Kumar Lohariwala
- Whole-Time Director
- Jayant Vasudeo Rao
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.